SCHEMBL2806295

SCHEMBL2806295

O=C1c2ccccc2C(=O)N1OCc1nc2cnc3ccccc3c2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.39
ATM Q13315 1/20 0.38
GAA P10253 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HTT P42858 1/20 0.37
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 2/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP2C9 P11712 1/20 0.34
RECQL P46063 1/20 0.34
MITF O75030 1/20 0.33
TP53 P04637 1/20 0.33
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GPR3 P46089 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806238 0.87 PTGES (0.37) MEN1KMT2AMAPTATMGAA
SCHEMBL2815272 0.79 TLR8 (0.57) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL2809228 0.78 NPC1 (0.41) KMT2AMAPTHTTNPC1SMN1; SMN2
SCHEMBL13128110 0.77 NPC1 (0.40) MEN1KMT2AMAPTHTTNPC1
SCHEMBL1528140 0.77 SMN1; SMN2 (0.43) KMT2AMAPTHTTNPC1SMN1; SMN2
SCHEMBL1528127 0.75 TLR8 (0.41) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL2807423 0.74 CYP1A2 (0.61) KMT2AMAPTALDH1A1HTTNPC1
SCHEMBL4970650 0.72 KMT2A (0.40) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL1527945 0.72 TLR8 (0.56) MAPTGAANPC1MAPK1RAB9A
SCHEMBL13128114 0.71 TLR8 (0.39) KDM4EGPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
EP-1877056-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLOÝ4,5-C¨RING COMPOUNDS AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-01-16 EP disclosed
WO-2007120121-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods IL4, IL2, TH MEN1 3807/4885KMT2A 2209/4885MAPT 3605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.